The regulatory effects of anti-angiogenic drugs targeting VEGFA/VEGFR2 in immune cells, including CD8+T cells, Tregs, MDSCs, DCs, tumor-associated macrophages and mast cells [28] were worth of further study. The gene discussed is KDR; the disease is neoplasm.